Join us:
January 10–12, 2021 in-person | San Francisco, CAJanuary 17–19, 2021 | Virtually

Victor E. Tong
Partner at Decheng Capital


Mr. Victor E. Tong, Jr. is a Partner at Decheng Capital and has been with the firm since its inception.

At Decheng, Mr. Tong focuses on investments in biotechnology and medical technology companies in China and US. Mr. Tong currently serves on the boards of AccuraGen, Cue Health, EpimAb Biotherapeutics, GenapSys, Hummingbird Bioscience, LevitasBio, Sema4, Take2 and Terns Pharmaceuticals. Mr. Tong also served as Chairman at ReadCoor, which was acquired by 10X Genomics. He previously served on the boards of Cirina (acquired by GRAIL / Illumina), GeneWEAVE Biosciences (acquired by Roche) and SentreHEART (acquired by Atricure).

Mr. Tong’s investment portfolio also includes 3SBio (1530.HK), Adaptive Biotechnologies (NASDAQ: ADPT), AK Medical (1789.HK), ARMO Biosciences (acquired by Eli Lilly), Cellular Research (acquired by Becton Dickinson), China Biologic Products (NASDAQ: CBPO), GenturaDx (acquired by Luminex), Hyperion Therapuetics (acquired by Horizon Pharma), Invitae (NASDAQ: NVTA), Ion Torrent Systems (acquired by Life Technologies), NextWave Pharmaceuticals (acquired by Pfizer), and SINOMED (688108.CH).

Prior to joining Decheng, Mr. Tong was a Principal at Bay City Capital and was a member of the founding team of Nevro (NYSE: NVRO), a Bay City Capital-originated medical device company. Prior to joining Bay City, Mr. Tong was an investment banker with Morgan Stanley, where he advised healthcare companies on initial public offerings and specialized in strategic advisory work. Prior to Morgan Stanley, Mr. Tong was an entrepreneur at Hana Biosciences (acquired by Spectrum Pharmaceuticals), where he was responsible for pipeline development, licensing and product launch for cancer products. Mr. Tong began his career participating in The Human Genome Project and its race to sequence the human genome as a research assistant at Incyte in 1999.

Mr. Tong is a graduate of the University of California, Berkeley, where he earned a BA degree in Molecular and Cell Biology and a BS degree in Business Administration from the Haas School of Business.

Agenda Sessions

  • Looking ahead – what to expect in the new world order

    On Demand